Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 8: | Line 8: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*8/8/2018: Initial approval for adult patients with relapsed or refractory [[Cutaneous T-cell lymphoma|mycosis fungoides (MF) or Sézary syndrome (SS)]] after at least one prior systemic therapy. ''(Based on MAVORIC)'' | *8/8/2018: Initial approval for adult patients with relapsed or refractory [[Cutaneous T-cell lymphoma|mycosis fungoides (MF) or Sézary syndrome (SS)]] after at least one prior systemic therapy. ''(Based on MAVORIC)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *11/22/2018: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' KW-0761 | *'''Code name:''' KW-0761 | ||
| Line 27: | Line 28: | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
| + | [[Category:EMA approved in 2018]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
Revision as of 23:52, 1 January 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. [1][2][3]
Diseases for which it is used
History of changes in FDA indication
- 8/8/2018: Initial approval for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. (Based on MAVORIC)
History of changes in EMA indication
- 11/22/2018: Initial authorization
Also known as
- Code name: KW-0761
- Generic name: mogamulizumab-kpkc
- Brand name: Poteligeo